Solitary fibrous tumor: features of the clinical course, radiation and laboratory diagnostics, therapy: A review

封面

如何引用文章

全文:

详细

Solitary fibrous tumor (SFT) is a relatively rare mesenchymal neoplasm, mainly affecting serous membranes and soft tissues.It is distinguished by a long-term course, a variable risk of metastasis, the possibility of occurrence in any anatomical region, as well as a low-specific histological structure.Moreover, the last two features of SFT are the main causes of diagnostic errors in morphological verification of a neoplasm. Despite the fact that in the twentieth century SFT was mentioned in the scientific literature quite rarely and, as a rule, in the form of single observations, in the last two decades, due to the widespread use of new molecular genetic research methods and the identification of specific mutations in mesenchymal tumors, the quality and accuracy have significantly increased. making a diagnosis. In addition, the clinical observations accumulated in recent decades in a considerable number of cases made it possible to assess in more detail the clinical and morphological parameters of the SFT associated with the risk of local recurrence and the appearance of distant metastases. This article analyzes the modern literature on epidemiology, molecular pathology, features of radiation and morphological diagnostics, aspects of the genesis of solitary fibrous tumor, as well as the choice of optimal treatment for patients.

作者简介

Nikolai Kozlov

Blokhin National Medical Research Center of Oncology

Email: newbox13@mail.ru
ORCID iD: 0000-0003-3852-3969

Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Anna Tsygankova

Blokhin National Medical Research Center of Oncology

Email: khalanskaya.anna@gmail.com
ORCID iD: 0000-0002-3165-5750

Graduate Student

俄罗斯联邦, Moscow

Amir Abdullaev

Blokhin National Medical Research Center of Oncology

编辑信件的主要联系方式.
Email: amirdo@mail.ru
ORCID iD: 0000-0003-0104-9087

D. Sci. (Med.)

俄罗斯联邦, Moscow

参考

  1. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumors of female reproductive organs, IARC, Lyon. 4th Edition. 2014; p. 85-101.
  2. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. IARC, Lyon. 2013; p. 468.
  3. Thway K, Ng W, Noujaim J, et al. The Current Status of Solitary Fibrous Tumor: Diagnostic Features, Variants, and Genetics. Int J Surg Pathol. 2016;24(4):281-92.
  4. Gholami S, Cassidy MR, Kirane A, et al. Size and Location Are the Most Important Risk Factors for Malignant Behavior in Resected Solitary Fibrous Tumors. Ann Surg Oncol. 2017;24(13):3865-71.
  5. Oda Y, Yamamoto H, Kohashi K, et al. Soft Tissue Sarcomas: From a Morphological to a Molecular Biological Approach. Pathol Int. 2017;67(9):435-46.
  6. Park HK, Yu DB, Sung M, et al. Molecular Changes in Solitary Fibrous Tumor Progression. J Mol Med (Berl). 2019;97(10):1413-25.
  7. Chuang IC, Liao KC, Huang HY, et al. NAB2-STAT6 Gene Fusion and STAT6 Immunoexpression in Extrathoracic Solitary Fibrous Tumors: The Association Between Fusion Variants and Locations. Pathol Int. 2016;66(5):288-96.
  8. Demicco EG, Fritchie KJ, Han A. Solitary Fibrous Tumour. In:/WHO Classification of Tumours Editorial board. Soft Tissue and Bone Tumours. IARC, Lyon. 2020; p. 104-8.
  9. Yamada Y, Kohashi K, Kinoshita I, et al. Clinicopathological Review of Solitary Fibrous Tumors: Dedifferentiation Is a Major Cause of Patient Death. Virchows Arch. 2019;475(4):467-77.
  10. Salas S, Resseguier N, Blay JY, et al. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Ann Oncol. 2017;28(8):1979-87.
  11. Olson NJ, Linos K. Dedifferentiated Solitary Fibrous Tumor: A Concise Review. Arch Pathol Lab Med. 2018;142(6):761-6.
  12. Pasquali S, Gronchi A, Strauss D, et al. Resectable Extra-Pleural and Extra-Meningeal Solitary Fibrous Tumours: A Multi-Centre Prognostic Study. Eur J Surg Oncol. 2016;42(7):1064-70.
  13. Diebold M, Soltermann A, Hottinger S, et al. Prognostic Value of MIB-1 Proliferation Index in Solitary Fibrous Tumors of the Pleura Implemented in a New Score – A Multicenter Study. Respir Res. 2017;18(1):210.
  14. Machado I, Nieto-Morales G, Cruz J, et al. Controversial Issues in Soft Tissue Solitary Fibrous Tumors: A Pathological and Molecular Review. Pathol Int. 2020;70(3):129-39.
  15. Robinson LA. Solitary fibrous tumor of the pleura. Cancer Control. 2006;13(4):264-9.
  16. DeVito N, Henderson E, Han G, et al. Clinical characteristics and outcomes for solitary fibrous tumor (SFT): a single center experience. PLoS One. 2015;10(10):e0140362. doi: 10.1371/journal.pone.0140362
  17. Ballo MT, Zagars GK, Cormier JN, et al. Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2004;58(5):1461-7. doi: 10.1016/j.ijrobp.2003.09.079
  18. Kawamura S, Nakamura T, Oya T, et al. Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy. Pathol Int. 2007;57(4):213-8. doi: 10.1111/j.1440-1827.2007.02083
  19. Dietrich CG, Roeb E, Breuer E, Matern S. Solitary fibrous thoracic wall tumor. Progression with percutaneous radiotherapy. Dtsch Med Wochenschr. 2001;126(1-2):12-5. doi: 10.1055/s-2001-9884
  20. Stacchiotti S, Negri T, Palassini E, et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther. 2010;9(5):1286-97. doi: 10.1158/1535-7163.MCT-09-1205
  21. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011;17(4):871-9. doi: 10.1158/1078-0432.CCR-10-2621
  22. Schwartz GK, Tap WD, Qin LX, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicenter, open-label, phase 2 trial. Lancet Oncol. 2013;14(4):371-82. doi: 10.1016/S1470-2045(13)70049-4
  23. Bahrami A, Lee S, Schaefer IM, et al. TERT Promoter Mutations and Prognosis in Solitary Fibrous Tumor. Mod Pathol. 2016;29(12):1511-22.
  24. Барышев В.В., Андреев В.Г., Акки Э.Д., и др. Солитарные фиброзные опухоли головы и шеи. Обзор проблемы. Сибирский онкологический журнал. 2016;15(1):67-72 [Baryshev VV, Andreev VG, Akki ED, et al. Solitarnye fibroznye opukholi golovy i shei. Obzor problemy. Sibirskii onkologicheskii zhurnal. 2016;15(1):67-72 (in Russian)].
  25. Полыновский А.В., Расулов А.О., Кузьмичев Д.В., и др. Успешный случай лечения пациента с солитарной фиброзной опухолью малого таза (клиническое наблюдение). Тазовая хирургия и онкология. 2017;7(4):64-70 [Polynovskii AV, Rasulov AO, Kuzmichev DV, et al. Uspeshnyi sluchai lecheniia patsienta s solitarnoi fibroznoi opukholiu malogo taza (klinicheskoe nabliudenie). Tazovaia khirurgiia i onkologiia. 2017;7(4):64-70 (in Russian)].

版权所有 © Consilium Medicum, 2021

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##